A Boston-based company has passed an important hurdle in its effort to get FDA approval for its ovarian-cancer treatment.
The newly approved medicines in 2024 from Massachusetts companies range from a schizophrenia drug to a gene therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback